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Abstract 
Background:  
We explored the establishment of abnormal blood brain barrier (BBB) permeability and its relationship 
to neuropathogenesis in early HIV by evaluating CSF:serum albumin quotient (QAlb) prior to and after 
combination antiretroviral therapy (cART) in primary HIV infection (PHI).  
 
Methods:  
QAlb was measured in longitudinal observational studies of PHI and in HIV-negative controls. We 
analyzed trajectories of QAlb pre- and post-cART using mixed-effects models, and associations between 
QAlb and CSF neurofilament light chain (NFL), N-acetylaspartate:creatinine (NAA:Cr, a magnetic 
resonance spectroscopy neuronal integrity biomarker), and neuropsychological testing. 
 
Results: 
Age-adjusted QAlb was elevated in PHI vs. controls at baseline (n=106, median 91 days post infection, 
dpi; n=64; p=0.02). Longitudinally pre-cART, QAlb increased in 84 participants with normal baseline 
QAlb (p=0.006), and decreased in 22 with high baseline QAlb (p=0.011). QAlb did not change after a 
median 398 days of cART initiated at 225 dpi (p=0.174). QAlb correlated at baseline and longitudinally 
with NFL (r=0.497, p<0.001; r=0.555, p<0.001) and NAA:Cr in parietal grey matter (r=-0.352, p<0.001, 
r=-0.387, p=0.008), but not neuropsychological performance.  
 
Conclusion: 
QAlb rises during early HIV, associates with neuronal injury, and does not significantly improve over a 
year of follow-up on treatment, suggesting that BBB-associated neuropathogenesis is initiated in early 
infection. 
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Introduction 
Chronic exposure to HIV can lead to neurological complications, with one third of untreated individuals 
with advanced AIDS developing HIV-associated dementia (HAD) [1, 2], a syndrome of severe 
cognitive, motor, and behavioral disturbances associated with cerebral atrophy, particularly of 
subcortical areas [3]. Although the incidence of HAD has significantly decreased with the advent of 
combination antiretroviral therapy (cART), a milder spectrum of neurocognitive deficits persists despite 
treatment [1, 2, 4]. As this persisting impairment may at least in part represent irreversible alterations of 
central nervous system (CNS) integrity accrued prior to the initiation of cART, investigative efforts have 
been drawn towards elucidating neuropathogenesis during the early stages of HIV neuroinvasion, and 
examining the effects of early cART on these processes.  
 Primary HIV infection (PHI) refers to the first phase of infection, from time of transmission up 
to 12 months post-transmission [5]. HIV infiltrates the CNS during PHI[6-8], as indicated by the 
presence of HIV RNA in the cerebrospinal fluid (CSF) compartment, even in the absence of 
neurological symptoms [1, 8-11]. CNS immune activation accompanies this viral invasion as reflected 
by elevations of CSF white blood count, the soluble CSF biomarkers neopterin (reflecting macrophage 
activation) and CXCL-10/IP-10 (a lymphocyte chemokine), and T lymphocyte activation in CSF[1, 12-
15]. Furthermore, markers of immune activation may reflect degree of viral load and neurocognitive 
impairment[16]. Magnetic resonance spectroscopy (MRS), a noninvasive quantitative MR technique that 
measures alterations in cerebral metabolism, demonstrates that inflammatory cerebral metabolites are 
elevated in acute HIV (prior to antibody seroconversion) and longitudinally increased over time in PHI 
prior to cART[1, 17, 18]. Thus, crucial processes during the primary phase of viral infection may 
underlie the initiation of HIV associated CNS injury.  
It is speculated that increased blood brain barrier (BBB) permeability is a critical contributor to 
HIV neuropathogenesis as disruption of this regulatory interface facilitates CNS infiltration of 
potentially harmful substances from the periphery, resulting in compounding viral entry and 
susceptibility to the inflammatory assault of immune cells[19, 20]. In order to exert its neurological 
effects, HIV-1 and/or its viral products must first traverse the BBB.  Although data suggest that at this 
initial stage, HIV is transported to the CNS via trafficking of infected immune cells across a largely 
intact BBB, increased permeability of the BBB has been implicated in the progression of HIV 
neurological dysfunction[19, 21-24]. The ratio of albumin in the CSF to serum albumin (CSF:serum 
albumin concentration quotient, or QAlb) is the best established fluid marker for BBB permeability[25]. 
Albumin is synthesized exclusively in the liver and is largely excluded from the CSF. Upon deregulation 
of the neurovascular unit and sequential loss of tight junctions, BBB permeability to albumin increases, 
resulting in an increased QAlb.  
In this study we aimed to elucidate the natural history of BBB permeability during PHI, and to 
determine whether these changes, if any, were associated with biomarkers of neuropathogenesis. 
Additionally, we sought to determine whether BBB permeability was responsive to cART treatment 
initiated during early HIV infection.  These studies provide novel understanding of the changes to the 
brain microenvironment that begin during initial HIV infection, and the persistence of these alterations 
in the setting of early, virologically suppressive cART. 
 
Materials and Methods 
 
Experimental design 
Individuals with PHI were recruited into prospective longitudinal studies of CNS HIV in Gothenburg, 
Sweden, and San Francisco, USA, between 1986 and 2014, as previously described [9]. Participants 
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were within the first year of HIV transmission as confirmed by the standard serologic testing algorithm 
for recent HIV seroconversion (STAHRS) [26], and all but three were ART-naive. A subset began 
cART at variable times during follow up for reasons outside of the study. None of the participants had a 
prior neurological disease history. A history of substance abuse was not an exclusion criterion, but no 
participants reported same-day substance abuse, which would have led to censoring of data.  Date of 
HIV transmission was approximated as 14 days prior to the onset of seroconversion symptoms, when 
present [27]; otherwise, it was approximated as midway between the dates of the last negative and first 
positive EIA test[28].  HIV-uninfected individuals from the community were enrolled at the San 
Francisco site for comparison of baseline parameters.   
 
Ethics 
The study protocol was approved by the institutional review board or an equivalent research ethics 
committee of each institution involved. All study participants gave written consent.  
 
Data collection and laboratory analysis 
CSF, blood, neuropsychological testing performance, and magnetic resonance spectroscopy (MRS) were 
obtained at each visit, and collection performed as previously described[23, 29].  Study intervals were 
scheduled at baseline (time 0), six weeks, and every six months thereafter, although there was 
participant variation in timing and duration of follow up. 
 
Blood CD4+ and CD8+ T-lymphocytes, CSF white blood cells, and CSF total protein were measured by 
flow cytometry.  CSF NFL was measured with the NF-light® ELISA kit (UmanDiagnostics AB, Umeå, 
Sweden), a sensitive immunoassay [21] with a lower limit of detection 50 ng/L, and reference values for 
upper limit of normal of 380 ng/L (18–30 years), 560 (30–39years), 890 (40–59 years), and 1850 (>59 
years)[21].  CSF and plasma albumin were measured by nephelometry (Behring Nephelometer 
Analyzer, Behringwerke AG, Marburg, Germany). QAlb was calculated as the CSF/plasma albumin ratio: 
CSF albumin (mg/l) / plasma albumin (g/l) [22]. Reference values for upper limit of normal were based 
on previously established values of <6.8 for age <45 years, and <10.2 for age >45 years [30].  HIV RNA 
was measured with the Abbott RealTime HIV-1 PCR assay (Abbot Laboratories, Abbot Park, IL, USA). 
Viral loads below the lower limit of detection (<50 copies/mL) were assigned a value of 49 copies/mL 
(1.69 on log10 scale).  
 
Neuropsychological performance was determined through the appraisal of gross and fine motor skills, 
processing speed, executive function, learning, and verbal memory through a battery of 11 tests. 
Performance was summarized as an aggregate total Z score and a brief NPZ-4 score (including grooved 
pegboard, digit symbol, finger tapping, and timed gait).  
 
MRI/MRS was obtained at the San Francisco site only.  A neuroradiologist reviewed MRI images to 
ensure that no significant non-HIV associated pathologies were present. MRS data was processed and 
analyzed with the spectral fitting software SITools, which uses a parametric model of known 
(metabolites) and modeled spectral components (macromolecules) to fit all resonances and 
nonparametric parameters to the baseline. Metabolite disturbances can indicate neuropathology, 
including inflammation and injury. The ratio of the cerebral metabolite N-acetylaspartate to creatinine 
(NAA:Cr) is a putative marker of neuronal viability and number. We focused on the parietal grey matter, 
as we have previously identified metabolite abnormalities in this region during primary infection in this 
cohort [17, 23].  
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Statistical analysis 
Non-parametric and parametric (ANCOVA) statistics were used to summarize baseline characteristics 
and compare findings between PHI and HIV-uninfected participants (significance level was set at p < 
0.05, two-sided). The mixed-effects model was used to analyze longitudinal change of QAlb post 
transmission. This model permits both fixed and random effects in the same analysis, allowing for 
variation in the number and time interval of participant follow-up visits. Baseline age was included as a 
fixed-effect covariate in the model. To account for a possible non-linear trajectory of QAlb over time, a 
quadratic term (t2) was included as a fixed-effect covariate. The model included a personal intercept for 
each participant as a random effect, allowing baseline QAlb to vary for each participant. An interaction 
term was initially added to assess whether the trajectory of QAlb over time depended on the baseline 
QAlb, but was found to be insignificant. As log-transformed results were comparable to non-log-
transformed analysis, the latter results are reported for familiarity of QAlb values. The graphed y-
intercept was calculated as follows: [(parameter estimate of baseline age)*(median age of 
subgroup)]+parameter estimate of subgroup intercept.  Statistical analyses employed SPSS 23.0 
statistical package (IBM Corp., Armonk, NY). 
  
Results 
 
Study participant characteristics 
106 PHI participants fulfilled the inclusion criteria and had available QAlb values. Only 9 participants 
experienced neurological disorders during seroconversion; these included meningitis (n=2), headache 
with photophobia (n=2), brachial neuritis (n=2), Guillain-Barre syndrome, facial palsy, and encephalitis.  
Total visits ranged from 1 to 13 with a median of 2, and follow-up ranged up to 2940 days with a 
median of 49.5 days. The majority of participants were infected with subtype B virus [9].  
  
The baseline characteristics of PHI and uninfected control participants are presented in Table 1. The 
median duration of HIV infection in PHI participants was 91 days; plasma viral load in PHI was 1.81 
log10 greater relative to that in the CSF compartment. As compared to the HIV-uninfected participants, 
the PHI cohort had a higher percentage of males, and was younger. As expected, PHI participants had a 
lower CD4 count, elevated CD8 count, and decreased CD4/CD8 ratio. As previously reported, CSF 
white blood cells were elevated in the PHI group, as well as CSF neopterin, a marker of macrophage 
activation. Despite the younger age, PHI participants had elevated NFL and equivalent CSF total protein 
to the uninfected group, two parameters that increase with normal aging [21, 31, 32].   
 
Blood brain barrier permeability at baseline 
At baseline, age adjusted QAlb was elevated in the PHI cohort compared to controls (means 5.9, 95% CI 
5.5 to 6.3 in PHI; and 5.0, 95% CI 4.4 to 5.6 in controls; p=0.02). Using previously published reference 
values[30], baseline QAlb was above the age-specific upper limit of normal (ULN) in 22 PHI participants 
(20.8%), referred to as the "high baseline QAlb subgroup." The remaining 84 PHI participants with 
baseline QAlb values below the ULN are referred to as the "normal baseline QAlb subgroup."  The 
baseline clinical characteristics of these two subgroups are summarized in Table 2.  4/22, or 18%, in the 
high baseline QAlb subgroup had neurosymptomatic seroconversion versus 5/84, or 6%, in the normal 
baseline QAlb subgroup. Elevated NFL, CSF total protein, CSF neopterin (but not blood neopterin), 
CD8+ T cell count, and a decreased plasma:CSF HIV RNA ratio were found in the high baseline QAlb as 
compared to normal baseline QAlb group.  
 6 
 
Longitudinal blood brain barrier permeability in PHI prior to cART 
The individual trajectories of each PHI participant's QAlb over the duration of the study prior to cART 
initiation are plotted in Figure 1. A mixed model analysis to evaluate the natural history of blood brain 
barrier integrity in the overall PHI group prior to cART did not reveal a significant change in QAlb over 
time (-0.000436/day, p=0.092). Figure 2 compares the trajectories of the high and normal baseline QAlb 
groups. The high baseline group showed a declining trend (-0.003/day, p=0.006) while the normal 
baseline group initially increased (0.00144/day, p= 0.004) and reached a plateau quickly (quadratic time 
effect p= 0.004).  
 
Correlation of blood brain barrier integrity with markers of neuropathogenesis 
To further evaluate the implications of an elevated QAlb, correlations between QAlb and markers of 
neuronal health were evaluated in pre-cART study intervals (Figure 3). Partial correlation coefficients 
were calculated to correct for the confounding effects of age, as QAlb and NFL both directly correlate 
with age. QAlb demonstrated a strong positive correlation with NFL, a marker of active neuronal injury, 
upon cross-sectional analysis at baseline (r=0.497, p<0.001), and longitudinally with both between-
participant (r=0.555, p<0.001) and within-participant analysis (r=0.523, p=0.001). QAlb inversely 
correlated with NAA:Cr, a cerebral metabolite biomarker of neuronal health, upon cross-sectional 
analysis at baseline (r=-0.352, p=0.015), and longitudinally with between-participant analysis (r=-0.387, 
p=0.008) but not within-participant analysis (r=0.218, p=0.125). QAlb did not correlate with composite z-
scores (total Z or NPZ4) of neuropsychological testing at baseline nor in longitudinal analysis.   
 
Characteristics of cART-treated study participants  
58 PHI participants initiated a cART regimen during study follow-up, although one participant was 
excluded for virologic failure (two consecutive plasma samples with HIV RNA >50 copies/mL after 6 
months of ART). Treatment regimens were heterogeneous, consisting of a combination of ⩾3 
antiretroviral agents. cART was initiated at a median  225 days post infection, with 402 days median on-
cART follow-up. Table 4 compares the cross-sectional laboratory parameters before (last visit before 
treatment) and after cART treatment (last visit of study) in those who initiated cART. There was 
improvement in most parameters after approximately a year of cART: suppression of plasma and CSF 
HIV RNA to the lower limit of PCR detection (p<0.001), increased CD4+ counts (p<0.001), decreased 
WBC count (p<0.001), and decreased blood and CSF neopterin (p<0.001). In this comparison, NFL and 
albumin ratio did not significantly change with cART treatment (640 vs 670, p=0.911; 5.18 vs 5.09, 
p=0.851). 
 
Longitudinal history of blood brain barrier integrity following cART initiation 
A mixed model analysis was performed to assess the longitudinal trajectory of QAlb over 13 months of 
cART (Figure 4). Three participants were recruited into the cohort already on cART (for 29, 27, and 19 
days) and thus included in the linear mixed model (n=60) but excluded from Table 4. As cART was 
initiated at a median of 225 dpi (t=0 on Figure 4), this time-point corresponded with the linear portion 
of Figure 2, where the acute quadratic changes of the normal baseline subgroup are resolving and 
reaching a set-point. Thus, initial analysis was performed with the total cART-treated group rather than 
separating into subgroups of high and normal baseline QAlb. There was no significant change detected in 
QAlb over the median >1 year duration of cART treatment (slope=-0.00369/month, p=0.174). With group 
stratification, the high baseline subgroup (n=7) demonstrated no significant change in QAlb over time 
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(p=0.783). The low baseline subgroup (n=53) demonstrated a slope of effectively zero 
(slope=0.00008/month, p=0.004), similar to the pre-cART plateau. 
 
Discussion 
In this study, we aimed to analyze the natural history of BBB permeability during the course of primary 
HIV infection, and the influence of early cART on this trajectory. We initially show that albumin ratio is 
mildly elevated in PHI participants as compared to uninfected controls when correcting for age. This 
correction is relevant given that BBB permeability increases with normal aging[33], and may explain 
why previous studies have not reported abnormalities in BBB permeability during PHI when compared 
to controls, particularly given that most early HIV studies enroll young patients. That being said, we 
have previously identified moderate elevation of albumin ratio in PHI [9, 34], and in chronic HIV 
participants who are cART-naive and neuroasymptomatic[9]. Similarly, Li et al have reported a strong 
association between matrix metalloproteinases--enzymatic surrogate markers of BBB permeability--and 
neurocognitive status in early HIV[35].  
 The novelty of this study is our finding that BBB permeability is undergoing dynamic changes 
early in the course of HIV infection, even within days of transmission. Two distinct trajectories were 
noted for the PHI cohort when stratified by baseline albumin ratio. Those with a normal baseline 
albumin ratio (below the ULN) showed a mild initial increase that plateaued within the first 1000 days 
of infection. Despite the initial rise, the QAlb remains well below the ULN. As will be discussed below, it 
may be that there is an element of sub-clinical injury associated with this mild rise.  The subgroup with 
high baseline albumin ratios demonstrated a marked decline in albumin ratio within the first 1000 days 
of infection. Presumably an early rise in albumin ratio occurred immediately following infection before 
participant recruitment, and is resolving during the follow up period. Notably, the subgroup with higher 
baseline albumin ratio was characterized by a higher percentage of neurosymptomatic seroconversion, 
elevations in CSF markers of axonal injury and immune activation, as well as a higher CSF-to-plasma 
HIV RNA ratio. These findings suggest that a subgroup of PHI participants is susceptible to marked 
BBB disruption, which persists even beyond 1000 days post infection, and is associated with signs of 
increased CNS involvement. Factors which predispose individuals to one trajectory versus the other 
warrant further investigation.  
 Upon revealing deregulation of BBB early in PHI, we were interested in determining the 
significance of these changes. Previous studies have expounded on the association of albumin ratio with 
biomarkers of CNS inflammation and injury[20]. We confirm that in PHI albumin ratio correlates 
strongly with the axonal injury marker, NFL[23], and newly demonstrate that it inversely correlates with 
the metabolic marker of neuronal health, NAA:Cr, which has not previously been shown. The utility of 
NFL is that it is a sensitive marker of active ongoing neuronal damage and its levels correlate with the 
severity of this damage [36-38]. We have previously shown NFL to be the most sensitive neuronal 
biomarker for assessing HIV neurodegeneration, as it can detect subclinical injury in 
neuroasymptomatic individuals, even in the early phase of infection [34, 39]. As disease progresses, it is 
also associated with overt clinical neurological disease, thus not only reflecting structural but functional 
changes[36]. However, it is not specific for HIV neurodegeneration, and thus must be interpreted with 
caution[34, 37]. We minimized this possibility by ensuring that none of the participants had comorbid 
neurological conditions at the study onset. Similar to QAlb, NFL was elevated in PHI but remained below 
the ULN (<560), possibly indicating subclinical damage, which may explain the lack of correlation with 
NPZ-4 testing. In line with this conclusion, we have previously shown a lack of correlation between 
NFL and NPZ-4 during PHI, despite showing moderate elevations when compared to uninfected 
controls [23, 34]. An additional disadvantage of NPZ-4 testing is that, unlike NFL, performance does 
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not distinguish active impairment from the residual defect of earlier pathologic neurological processes. 
Similar to the utility of NFL as a biomarker of early subclinical injury, MRS has been shown to detect 
early HIV neuropathogenesis prior to conventional MRI changes[40].  In a recent study, chronically 
infected HIV subjects with cognitive defects were shown to have reduced glutamate and NAA in several 
brain regions, but most pronounced in the parietal grey matter[41]. Here, we extend that finding to the 
earliest stage of infection.  
 Once we demonstrated that BBB permeability was altered in PHI, and associated with markers 
of neuronal pathology, we assessed whether early cART treatment could remediate these changes. 
Surprisingly, the effect of cART on BBB permeability has not been intensely evaluated. In an 
unpublished study, Crozier and colleagues observed the gradual diminishment of albumin ratio (median 
6.48 to 6.09) in 16 neuroasymptomatic participants with chronic HIV infection after 200 days of cART 
therapy[42]; thus, although BBB integrity improved over time with cART therapy, a return to baseline 
or near baseline function may take years. In contrast, Abdulle and colleagues reported no significant 
reduction in BBB permeability after 2 years of cART treatment in 38 neuroasymptomatic 
participants[43]. Importantly, the median baseline albumin ratio of participants in the Crozier study was 
greater than that of participants in the Abdulle study (6.48 vs 4.45), potentially contributing to the 
discrepancy in cohort response to cART.   
 In our study, cART treatment, initiated at a median of 225 days post infection, was effective in 
suppressing CSF and plasma HIV RNA, suggesting medication compliance and effectiveness. Notably, 
the inflammatory marker neopterin improved to the upper level of normal limits both in the plasma and 
CSF. Despite this systemic (including CNS) suppression of viral replication and inflammation, NFL and 
albumin ratio were unchanged. The pre-cART measurement of albumin ratio is comparable to the age-
matched uninfected controls, and thus may indicate that the acute changes of albumin ratio in the high 
baseline sub-group had largely resolved and reached near-baseline once cART was initiated at 225 days 
post infection.  On the other hand, although NFL is below the age-specific ULN (<840), it is 
significantly elevated compared to uninfected controls and the baseline PHI cohort, given only a 
marginal age difference. Although the half-life of NFL is not established, there is a gradual 
normalization of NFL following axonal injury which is unlikely to persist for over a year[44]. Thus, this 
persistently elevated level of NFL may reflect continued subclinical injury despite cART treatment and 
what appears to be a largely normal albumin ratio.  
 We hypothesize that perhaps (1) the initially altered BBB permeability has initiated CNS injury 
which persists despite resolution of BBB integrity, (2) the mechanism of injury is independent of BBB 
integrity, or (3) BBB permeability is mildly elevated and has not fully returned to baseline resulting in 
persisting neuronal injury. Alternatively, it is possible that despite the large sample size, we still have 
insufficient power to detect a significant change in NFL and QAlb after cART. Further studies are 
necessary to elucidate the possible explanation. Notably, a previous study showed normalization of the 
CD4/CD8 ratio during PHI only when cART was initiated within 6 months of transmission[45].  
Furthermore, in a cohort of individuals started on treatment during acute HIV, CSF NFL was not 
elevated at baseline nor after 6 and 24 months of cART[46]. The effects of earlier cART intervention on 
albumin ratio normalization should be investigated.  
 
Limitations 
The conclusions from our study depend on the reliability of QAlb as a marker of BBB permeability. As 
QAlb is a ratio, it is a relatively method-independent parameter, thus reference values continue to be 
reliable despite difference in laboratory equipment or technique[33]. Notably, total CSF protein is an 
absolute measurement and is influenced by intrathecal protein synthesis, unlike QAlb, thus accounting for 
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possible discrepancies between the two measurements in this study. QAlb is affected by many factors not 
accounted for in this study, including body weight and smoking[33]. Abuse of substances such as 
cocaine has been shown to at least transiently increase BBB permeability[47]; thus, misreporting of 
ongoing drug use or long-term effects of previous drug use cannot be discounted as confounding factors. 
Furthermore, given the observational nature of this study, cART regimens were heterogeneous which 
may result in distinct effects on the BBB. Some researchers caution against describing this measure as a 
blood-brain barrier test and state that it actually reflects the blood-CSF barrier at the choroid plexus (ref: 
Reiber, H. & Peter, J.B. Cerebrospinal fluid analysis: disease-related data patterns and evaluation 
programs. J Neurol Sci 184, 101-122, 2001). However, in for example stroke, leaving the choroid plexus 
intact but injuring cerebrovascular endothelial cells, the CSF/serum albumin ratio may be increased (ref: 
Brouns, R., Wauters, A., De Surgeloose, D., Marien, P. & De Deyn, P.P. Biochemical markers for 
blood-brain barrier dysfunction in acute ischemic stroke correlate with evolution and outcome. Eur 
Neurol 65, 23-31, 2011), suggesting that CSF/serum albumin ratio probably is a marker of both barriers. 
 
Conclusions 
Blood brain barrier permeability undergoes a dynamic process early in HIV infection, demonstrating 
acute changes within days. We identified two subgroups of PHI participants with different albumin ratio 
trajectories: one with a presumed acute increase and gradual improvement over the course of infection, 
and a second with a mild initial increase. BBB permeability correlated with markers of 
neuropathogenesis. Initiation of cART in the first year of infection did not significantly alter BBB 
permeability in our study. Further investigations should test the effects of earlier cART initiation, 
especially in individuals with signs of early BBB disruption.  
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